Cargando…
Current Strategies of Antiviral Drug Discovery for COVID-19
SARS-CoV-2 belongs to the family of enveloped, single-strand RNA viruses known as Betacoronavirus in Coronaviridae, first reported late 2019 in China. It has since been circulating world-wide, causing the COVID-19 epidemic with high infectivity and fatality rates. As of the beginning of April 2021,...
Autores principales: | Mei, Miao, Tan, Xu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155633/ https://www.ncbi.nlm.nih.gov/pubmed/34055887 http://dx.doi.org/10.3389/fmolb.2021.671263 |
Ejemplares similares
-
Current Perspectives in the Discovery of Newer Medications Against the Outbreak of COVID-19
por: Ramesh, M., et al.
Publicado: (2021) -
Editorial: Antiviral drug discovery against pathogens of pandemic concern: Advancements in target site identification and structure-based drug development
por: Padmanabha Das, Krishna M.
Publicado: (2023) -
Discovery of Potential Flavonoid Inhibitors Against COVID-19 3CL Proteinase Based on Virtual Screening Strategy
por: Xu, Zhongren, et al.
Publicado: (2020) -
Drug discovery by a basic research scientist
por: Eaton, William A.
Publicado: (2022) -
A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials
por: Venkadapathi, Jeyanthi, et al.
Publicado: (2021)